Australia appears to be gain access to innovative therapy for obesity: Retatrutide. This dual compound – targeting on both GLP-1 and GIP receptors – has promising outcomes in international studies, pointing to substantial reductions in BMI. While availability is pending with the Therapeutic Goods Administration (TGA), a number of individuals de… Read More